Cited by 19Pancreatic function and diabetesDiabetes Management and ResearchDiabetes Treatment and Management

Effects of intranasal insulin on endogenous glucose production in insulin‐resistant men

Xiao, Changting, Dash, Satya, Stahel, Priska, Lewis, Gary F.·2018·Diabetes, Obesity and Metabolism

Abstract

The effects of intranasal insulin on the regulation of endogenous glucose production (EGP) in individuals with insulin resistance were assessed in a single‐blind, crossover study. Overweight or obese insulin‐resistant men ( n = 7; body mass index 35.4 ± 4.4 kg/m 2 , homeostatic model assessment of insulin resistance 5.6 ± 1.6) received intranasal spray of either 40 IU insulin lispro or placebo in 2 randomized visits. Acute systemic spillover of intranasal insulin into the circulation was matched with a 30‐minute intravenous infusion of insulin lispro in the nasal placebo arm. EGP was assessed under conditions of a pancreatic clamp with a primed, constant infusion of glucose tracer. Under these experimental conditions, compared with placebo, intranasal administration of insulin did not significantly affect plasma glucose concentrations, EGP or glucose disposal in overweight/obese, insulin‐resistant men, in contrast to our previous study, in which an equivalent dose of intranasal insulin significantly suppressed EGP in lean, insulin‐sensitive men. Insulin resistance is probably associated with impairment in centrally mediated insulin suppression of EGP.

Integrity signals

Registry

Crossref · 10.1111/dom.13289

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In pancreatic clamps with a primed, constant infusion of glucose tracers, IN administration of 40 IU insulin lispro compared with placebo suppressed endogenous glucose production only in normal-weight participants.

    “In the latter set of experiments, 83,84 the IN administration of 40 IU of insulin lispro, another rapid-acting insulin analogue, in comparison with placebo, suppressed endogenous glucose production only in the normal-weight participants.”

    From Intranasal insulin (2021) · cites this paper as [84]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Xiao, C., Dash, S., Stahel, P., & Lewis, G. F.
Affiliations
University of Toronto (CA)
Corresponding author
Lewis, Gary F.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-04-14
Volume
20
Issue
7
Pages
1751-1754
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2792803451
Cited by
19
References
15
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 1
FWCI
2.60
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Diabetes Canada
  • Drucker Family Chair in Diabetes Research
  • Sun Life Financial Chair in Diabetes
  • Banting and Best Diabetes Centre Hugh Sellers Postdoctoral Fellowship and a Diabetes Action Canada Postdoctoral Fellowship
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
intranasal insulin, endogenous glucose production, insulin resistance, insulin lispro, glucose disposal, obesity, overweight men, glucose tracer
MeSH terms
Administration, Intranasal, Adult, Blood Glucose, Gluconeogenesis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Middle Aged, Obesity, Glucose Clamp Technique, Single-Blind Method, Cross-Over Studies, Overweight, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review